Monoaminergic hypothesis of depression
======================================

The monoaminergic hypothesis of depression posits that this illness results from a deficit in serotonin (5-HT), noradrenaline, and dopamine signaling in the brain. Of these monoamines, the serotonergic system has been the one most strongly implicated in the pathophysiology and treatment of mood disorders. Although this relationship has not been proven, many findings indirectly support this hypothesis: (a) a subgroup of depressed patients have a very marked reduction of the concentration of 5-HT in plasma ([@bib24]) and of its metabolite, 5-hydroxyindoleacetic acid, in the cerebrospinal fluid ([@bib5]) that may reflect decreased serotonergic transmission in the brain; (b) most prescribed antidepressant drugs increase serotonergic transmission in the long term; (c) a clinical study showed that in ∼50% of depressed patients that responded to selective 5-HT reuptake inhibitors (SSRIs) (see [Fig. 1](#fig1){ref-type="fig"}), depressive symptoms relapsed after depletion of the 5-HT precursor tryptophan ([@bib11]); (d) recent preclinical investigations have reported that an intact serotonergic system is required for an antidepressant response to experimental treatments such as deep brain stimulation or ketamine ([@bib14]; [@bib12]); and (e) optogenetic activation of the prefrontal cortex projection to the dorsal raphe (DR) nucleus produces antidepressant-like effects in rodents ([@bib9]; [@bib28]). Therefore, there is evidence that deficits in serotonergic transmission are associated with at least some depressive states and a poor response to antidepressant drugs ([@bib23]), whereas the activation of 5-HT neurons in the DR evokes an antidepressant response.

Role of raphe 5-HT in the effects of antidepressant drugs
=========================================================

Most serotonergic neurons originate in the DR nucleus found in the brainstem. This nucleus is highly enriched in 5-HT transporters (SERTs) and in inhibitory 5-HT~1A~ autoreceptors. Although the roles of extracellular 5-HT and 5-HT~1A~ autoreceptors in the DR have been studied extensively ([@bib19]; [@bib3]), their exact function remains unclear. Some studies have shown that 5-HT~1A~ autoreceptors function as sensors that respond only when the concentration of endogenous 5-HT in the extracellular compartment becomes excessive ([@bib3]), whereas other work has provided evidence for tonic activation of 5-HT~1A~ autoreceptors under certain experimental conditions ([@bib13]). It was first demonstrated in the early 90s that current antidepressant drugs predominantly increase extracellular 5-HT in the raphe region ([@bib1]; [@bib15]), thereby activating inhibitory 5-HT~1A~ autoreceptors, reducing cell firing, and having a negative feedback influence on 5-HT release. Thus, it is likely that the rapid pharmacological action of SSRIs (and other antidepressant drugs) in the DR---desired to act like an accelerator---initially act as a brake in the therapeutic process.

Several recent studies support this contention. Thus, the selective knockdown of presynaptic 5-HT~1A~ (autoreceptors) but not postsynaptic 5-HT~1A~ receptors by small-interfering RNA (siRNA) results in clear-cut antidepressant-like behaviors in mice ([@bib6]). In contrast, mice that overexpress the DR 5-HT~1A~ receptor exhibit increased behavioral despair, and no behavioral response to antidepressant drugs ([@bib22]). This is consistent with clinical data showing that people with increased density or activity of 5-HT~1A~ autoreceptors are more susceptible to mood disorders and respond poorly to antidepressant treatments ([@bib26]; [@bib18]). It is thus evident that the serotonergic transmission in projection areas is controlled, at least in part, by basal serotonergic activity on somatodendritic 5-HT~1A~ autoreceptors on serotonergic neurons in the raphe ([@bib25]; [@bib21]; [@bib10]). Importantly, it is of note that there is a substantial delay in the therapeutic effect of SSRIs, and it has been subsequently postulated that autoinhibitory control caused by increased extracellular raphe 5-HT might be responsible for this delay ([@bib4]). Therefore, it is critical to identify the release mechanisms that fill the extracellular compartment of the DR with 5-HT.

Mechanisms of 5-HT release in the raphe nuclei
==============================================

SSRIs produce a sustained increase in extracellular 5-HT in the DR, and this leads to autoinhibition of serotonergic neurons. However, it is clear that, even though the 5-HT~1A~ autoreceptors are activated by extracellular 5-HT, the transmitter must be released in some way (presumably independent of 5-HT cell firing) to replenish the extracellular pool. Various mechanisms have been suggested to explain the local release of 5-HT from DR neurons in the raphe nucleus. Several earlier studies suggested that extracellular 5-HT in the raphe nuclei depended on neuronal stimulation and release from storage vesicles by exocytosis ([@bib16]; [@bib20]; [@bib27]) (see [Fig. 1](#fig1){ref-type="fig"}). The thorough study by Mlinar et al. (2015) now shows for the first time that substantial nonexocytotic 5-HT release takes place in the absence of neuronal activity, Ca^2+^ influx, or vesicular monoamine transporter 2--mediated vesicular accumulation of 5-HT. Furthermore, Mlinar et al. elegantly demonstrate that blockade of SERT by an SSRI does not disrupt nonexocytotic release of 5-HT, ruling out the possibility that it depends on reverse transport by SERT. Collectively, their results suggest that a prominent fraction of extracellular 5-HT in the raphe nuclei is released from a cytoplasmic pool by simple diffusion across the plasma membrane. These results contrast with those of [@bib7], who observed action potential--independent, but vesicle-dependent release of 5-HT from dendrites. Further research is needed to determine whether the cytoplasmic 5-HT identified by [@bib17] represents a "functional" transmitter pool in the DR, i.e., if it has physiological and behavioral consequences.
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Notably, [@bib17] performed their analyses in slices of brainstem exposed to the α~1~-adrenoceptor agonist, phenylephrine, and a cocktail of drugs indicative of a lack of glutamatergic and GABAergic tone on 5-HT release from serotonergic neurons. These findings strongly suggest that glutamatergic and GABAergic inputs to the DR do not contribute substantially to 5-HT cell autoinhibition. Moreover, the results are indicative of a relative scarcity of serotonergic transmission in the DR measured as the probability of evoking serotonergic inhibitory postsynaptic potentials (IPSC~5-HT~) in serotonergic neurons. Most of the recorded neurons were located in the dorsal and the ventromedial part of the DR, and higher IPSC~5-HT~ success rates were reported in slices containing the centrocaudal extent of DR, which is the subdomain of the nucleus that projects to areas in the hippocampus that influence theta activity ([@bib8]), thought to underlie learning and memory.

Future prospects
================

Depression is the most common neuropsychiatric disorder and, according to World Health Organization, is predicted to be the second leading cause of global disability burden by 2020. Most existing antidepressant drugs target the serotonergic system but, unfortunately, they fall short of being adequate for a large subset of patients. One of the main drawbacks of such therapy is the therapeutic delay of SSRIs, for which the increase in extracellular 5-HT in the raphe nuclei is postulated to be a key factor. To overcome this problem, it is important to characterize the precise mechanism(s) of transmitter release in this structure. Previous work has shown that there are multiple ways to induce 5-HT release in raphe nuclei, as also observed in the forebrain ([@bib2]). The study of [@bib17] uses an in vitro preparation to describe in detail a new mechanism of nonexocytotic and nonvesicular release of 5-HT in the raphe nuclei. An important feature of this process is that it is not performed by reversal of SERT, which means that it cannot be inhibited by SSRIs. The in vitro nature of the study is a clear limitation and further research is needed to determine its therapeutic potential. Should this nonexocytotic release of 5-HT in the raphe nuclei occur in vivo, it would represent an important target for antidepressant drugs inasmuch as raphe 5-HT exerts a fine tuning of the control of serotonergic transmission throughout the brain.
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